Day: May 12, 2022

Registrational study design for lead clinical asset, EB613, as the first oral PTH anabolic to treat post-menopausal women at high risk of osteoporosis, is underway Company reschedules conference call and webcast to Wednesday, May 18 at 8:00 AM EDT BOSTON and JERUSALEM, May 12, 2022 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced its financial and operating results for the quarter ended March 31, 2022. First Quarter 2022 and Recent Highlights EB613 Clinical Update: Entera’s lead clinical candidate, EB613, an oral formulation of human parathyroid hormone (1-34), or PTH, for the treatment of osteoporosis, is progressing towards a pivotal Phase 3 clinical trial. The FDA has completed the Chemistry Manufacturing and Control (CMC) review...

– Phase 3 Lumeos Clinical Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) Actively Dosing Patients– Phase 1 AQUAx Study of AAV-hAQP1 for Radiation-Induced Xerostomia Completed Dosing of Both Unilateral and Bilateral Cohorts in the First Quarter of 2022 LONDON and NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) — MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the first quarter ended March 31, 2022 and provided an update on recent progress. “During the first quarter of this year, we continued to progress our lead program for the treatment of XLRP, botaretigene sparoparvovec, through pivotal development along with our partner Janssen,” said Alexandria Forbes, Ph.D., president and chief...

Total net revenues up 7.4% to $14.8 million in Q3 FY 2022 Annual recurring revenue (SaaS and Support) increased to a $26.2 million run rate CALABASAS, Calif., May 12, 2022 (GLOBE NEWSWIRE) — NETSOL Technologies, Inc. (Nasdaq: NTWK), a global business services and enterprise application solutions provider, reported results for the fiscal third quarter ended March 31, 2022. Fiscal Third Quarter 2022 and Recent Operational HighlightsSubscription (SaaS and Cloud) and support quarterly revenues increased 16% to $6.6 million. NETSOL’s U.S. based mobility startup Otoz expanded its digital automotive retail platform MINI Anywhere® for BMW® Group Financial Services in the U.S. for its key brand MINI®. MINI Anywhere is now live with 17 MINI dealerships, including 70%+ of the California MINI dealerships and 75% of all Pennsylvania dealerships....

Validive® Phase 2b/3 VOICE Trial Continues Enrolling Patients Toward InterimCamsirubicin Phase 1b Dose-Escalation Trial Clears 3rdDose Level, Now Enrolling 4th WILMETTE, Ill., May 12, 2022 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced first quarter 2022 financial results and summarized recent program developments. Recent Program Developments Validive – International Phase 2b/3 VOICE Clinical Trial, Actively RecruitingThe VOICE trial continues to enroll patients and add additional clinical sites, with the interim analysis anticipated to occur in 2H-2022.Camsirubicin – Phase 1b Dose-Escalation Trial, Actively...

First Quarter Highlights – 2022 vs. 2021Revenue up 39% to $6.2 million from $4.4 millionOperating income increases 6-fold to $0.6 million from $0.1 millionNet income of $0.5 million vs. $1.2 million in year-ago first quarter when Company booked $1.0 million in PPP loan forgiveness in other incomeAdjusted EBITDA of $0.9 million, up 156% from $0.4 millionCompany buys back 33,550 shares of stock in the first quarterCASTLE ROCK, Colo., May 12, 2022 (GLOBE NEWSWIRE) — Where Food Comes From, Inc. (WFCF) (Nasdaq: WFCF), the most trusted resource for independent, third-party verification of food production practices in North America, today announced financial results for its first quarter ended March 31, 2022. “First quarter revenue growth reflected continued momentum in our verification and certification segment, including...

Viactiv® Generated Net Revenues of approximately $2.3 Million or 95% of Net Revenues for the Quarter Ended March 31, 2022 HOUSTON, May 12, 2022 (GLOBE NEWSWIRE) — Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced its financial results for the quarter ended March 31, 2022. The Company also provided a corporate update to shareholders. The financial highlights presented below were materially impacted by the Company’s June 1, 2021 acquisition of the Viactiv® line of supplement chews for bone health, immune health and other applications, which are profitably marketed through many of the nation’s...

REHOVOT, Israel, May 12, 2022 (GLOBE NEWSWIRE) — Purple Biotech Ltd. (“Purple Biotech”, or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced financial results for the first quarter ended March 31, 2022. “We were focused in the clinical advancement of our promising first in class oncology drug candidates during this quarter,” said Gil Efron, President and Chief Financial Officer of Purple Biotech. “For NT219, we completed enrollment in the fourth dose level of the monotherapy arm of the ongoing Phase 1/2 clinical trial and will soon start the last dose level planned in the dose escalation part of the monotherapy arm. For CM24, we will soon initiate the expansion arms...

* MIND CTI to Host Annual Meeting of Shareholders** Release of New e-commerce Module YOQNEAM, Israel, May 12, 2022 (GLOBE NEWSWIRE) — MIND C.T.I. LTD. – (NasdaqGM:MNDO), a leading provider of convergent end-to-end prepaid/postpaid billing and customer care product-based solutions for service providers, unified communications analytics and call accounting solutions for enterprises as well as enterprise messaging solutions, today announced results for its first quarter ended March 31, 2022. The following will summarize our major achievements in the first quarter of 2022, as well as our business. The financial results can be found in the Company News section of our website at http://www.mindcti.com/company/news/ and in our Form 6-K. Financial HighlightsRevenues were $5.7 million, compared with $6.1 million in the first quarter...